Recent articles
Here's Why Fluidigm Soared as Much as 58.6% Today
The struggling laboratory hardware developer received a $37 million infusion to tackle the coronavirus pandemic.
Coronavirus Vaccine Stocks: Investors Cannot Overlook These Risks
If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.
Here's Why MediciNova Is Soaring Today
The small-cap pharmaceutical company announced a collaboration to develop a coronavirus vaccine.
Here's Why Amyris Stock Rose as Much as 12.2% Today
The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.
Missing in the Hydrogen Economy Pitch: The Tax Credit Cliff for Fuel Cells
Fuel-cell manufacturers have fixed the eyes of investors on the growth potential of a hydrogen economy, but it might be distracting from a looming financial crunch.
Twist Bioscience Has Gained 186% in 2020. Is the Synbio Stock a Buy?
The company's $2.7 billion valuation is being driven by the coronavirus pandemic and federal stimulus. It doesn't appear sustainable.
U.S. Uranium Output Hit an All-Time Low in 2019. Does It Matter?
Nuclear power plants provide roughly 20% of the nation's electricity, but domestic uranium production could have met just 0.4% of fuel requirements last year.
2 Stocks to Hold for the Next 20 Years
Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
Fuel Cell Investors Shouldn't Get Too Caught Up in the Hydrogen Economy Just Yet
Dreams of a hydrogen future have sent fuel cell stocks soaring in 2020, but investors might get burned by the technological hype.
Renewable Energy Is the New Growth Driver for Dominion Energy
The unexpected sale of its gas transmission and storage business makes regulated utility operations, and renewable energy, more important than ever.
Is Neoleukin Therapeutics a Buy?
The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.
About to Buy Penny Stocks? Look at These 2 Companies First
These two healthcare stocks are risky, but they have much better chances of success than penny stocks.
Here's Why MacroGenics Jumped 156.6% in the First Half of 2020
Investors remain optimistic that the leading drug candidate can earn marketing approval before the end of the year.
Here's Why SolarEdge Technologies Jumped 46% in the First Half of 2020
After a brief tumble in March, the clean energy company is trading at an all-time high.
Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020
Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.
Here's Why Incyte Rose 19.1% in the First Half of 2020
Incyte might finally be convincing Wall Street that its pipeline is the real deal.
Here's Why Elanco Animal Health Fell 27.2% in the First Half of 2020
The animal health company's reliance on livestock has proved a risk during an uncertain year. Can a massive acquisition change that?
Here's Why Beyond Meat Soared 77.2% in the First Half of 2020
The animal-free protein developer clawed its way back after a disappointing second half of 2019.
Here's Why Axsome Therapeutics Fell 20.4% in the First Half of 2020
One of the best investments of 2019 fell on hard times in the first six months of 2020, but it's not as bad as it seems.
Here's Why Amarin Tumbled 67.7% in the First Half of 2020
The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction.